文献速递前列腺癌

计算机主导的前列腺癌随访多中心验证:有效且安全

A multicentre integration of a computer-led follow-up of prostate cancer is valid and safe.
PubMed 文献 · BJU Int · 2018-03-06

本研究在英国两家医院验证计算机临床决策支持系统(CDSS)用于前列腺癌治疗后随访。对200例患者数据,CDSS与两位独立泌尿外科顾问的决策一致性kappa为0.81和0.84(P<0.001),系统重复性达100%。结论认为CDSS随访是安全有效的模式。

要点

  • CDSS与两位泌尿外科顾问决策一致性高,kappa分别为0.81和0.84。
  • 两位顾问间一致性kappa为0.83,系统决策重复性达100%。
  • CDSS随访可作为前列腺癌治疗后安全随访的有效模型。

核心结论

  • CDSS随访是提供前列腺癌安全随访的有效模型。

研究设计与样本

  • 基于欧洲泌尿外科学会(EAU)和英国国家卫生与临床优化研究所(NICE)指南及泌尿外科医生知识开发CDSS,在英国两家医院对200例前列腺癌治疗后患者数据进行回顾性验证。

主要发现

  • 两位独立泌尿外科顾问分别识别12%和15%的患者存在潜在疾病进展并建议转诊泌尿外科。
  • CDSS与两位顾问决策一致性kappa分别为0.81(P<0.001)和0.84(P<0.001)。
  • 两位顾问间一致性kappa为0.83(P<0.001)。
  • 系统在所有病例中决策重复性达100%。

临床怎么用

  • CDSS可依据患者血液检查和临床情况辅助判断疾病复发或治疗失败,支持前列腺癌治疗后随访决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test a computer-led follow-up service for prostate cancer in two UK hospitals; the testing aimed to validate the computer expert system in making clinical decisions according to the individual patient's clinical need with a valid model accurately identify patients with disease recurrence or treatment failure based on their blood test and clinical picture. PATIENTS AND METHODS: A clinical-decision support system (CDSS) was developed from European (European Association of Urology) and national (National Institute for Health and Care Excellence) guidelines along with knowledge acquired from Urologists. This model was then applied in two UK hospitals to review patients after prostate cancer treatment. These patients' data (n = 200) were then reviewed by two independent urology consultants (blinded from the CDSS and the other consultant's rating) and the agreement was calculated by kappa statistics for validation. The second endpoint was to verify the system by estimating the system reliability. RESULTS: The two individual urology consultants identified 12% and 15% of the patients to have potential disease progression and recommended their referral to urology care. The kappa coefficient for the agreement between the CDSS and the two consultants was 0.81 (P < 0.001) and 0.84 (P < 0.001). The agreement amongst both specialist was also high with k = 0.83 (P < 0.001). The system reliability was estimated on all cases and this demonstrated 100% repeatability of the decisions. CONCLUSION: A CDSS follow-up is a valid model for providing safe follow-up for prostate cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Salem HA, Caddeo G, McFarlane J, et al. A multicentre integration of a computer-led follow-up of prostate cancer is valid and safe. BJU Int. 2018. PMID: 29393997. doi:10.1111/bju.14157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。